



## UvA-DARE (Digital Academic Repository)

### Genomic Data as a National Strategic Resource

*Implications for the Genomic Commons and International Data Sharing for Biomedical Research and Innovation*

McKibbin, K.; Shabani, M.

**DOI**

[10.1017/jme.2023.77](https://doi.org/10.1017/jme.2023.77)

**Publication date**

2023

**Document Version**

Final published version

**Published in**

The Journal of law, medicine & ethics

**License**

Article 25fa Dutch Copyright Act (<https://www.openaccess.nl/en/in-the-netherlands/you-share-we-take-care>)

[Link to publication](#)

**Citation for published version (APA):**

McKibbin, K., & Shabani, M. (2023). Genomic Data as a National Strategic Resource: Implications for the Genomic Commons and International Data Sharing for Biomedical Research and Innovation. *The Journal of law, medicine & ethics*, 51(2), 301-313. <https://doi.org/10.1017/jme.2023.77>

**General rights**

It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

**Disclaimer/Complaints regulations**

If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: <https://uba.uva.nl/en/contact>, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.

*UvA-DARE is a service provided by the library of the University of Amsterdam (<https://dare.uva.nl>)*

# Genomic Data as a National Strategic Resource: Implications for the Genomic Commons and International Data Sharing for Biomedical Research and Innovation

*Kyle McKibbin*<sup>1</sup>  
and *Mahsa Shabani*<sup>1</sup>

<sup>1</sup>: GHENT UNIVERSITY, GHENT, BELGIUM.

**Keywords:** Information Commons, Research, International Collaboration, Data Sharing, Nationalism

**Abstract:** This article provides a critical review of new policies in China, the United States, and the European Union that characterize genomic data as a national strategic resource. Specifically, we review policies that regulate human genomic data for economic, national security, or other strategic purposes rather than ethical or individual rights purposes.

For the past 30 years, beginning with the policies surrounding the Human Genome Project (HGP), researchers, policy makers, journals, and funding agencies around the world have worked towards building an information commons of human genomic data. This commons, as expounded on by Contreras and Knoppers, is a worldwide collection of publicly accessible human genomic data housed in a variety of privately and publicly funded databases and governed by a consistent set of principles regarding privacy, use, openness, and access.<sup>1</sup> This global public resource has served as the basis for countless biomedical discoveries in the past two decades<sup>2</sup> and as a model for various medical information commons and open science frameworks that have proliferated in recent years.<sup>3</sup> Of course, managing this increasingly complex collection of data is an ongoing challenge, and researchers grapple with data sharing complexities arising from access management, interoperability, and data protection laws.<sup>4</sup> Nevertheless, there is a clear consensus that the need for widespread data sharing and international collaboration in the field of genomics has never been greater.<sup>5</sup> Deploying new healthcare technologies,<sup>6</sup> developing new personalized treatments,<sup>7</sup> and managing public health crises,<sup>8</sup> all while working towards more equitable access to the benefits of health research,<sup>9</sup> will require data collection and collaboration on a more integrated and international scale.

In contrast to the needs of the biomedical research and healthcare communities, there is growing evidence of a paradigm shift in national policy toward human genomic data in China, the United States (US), and the European Union (EU) that threatens to derail the policies and objectives of the genomic

**Kyle McKibbin, J.D.**, is a postdoctoral researcher at Ghent University's Faculty of Law and Criminology. **Mahsa Shabani, Ph.D.**, is an Assistant Professor in Privacy Law at Ghent University's Faculty of Law and Criminology.

commons. As we will outline in this paper, policymakers in these jurisdictions increasingly categorize collections of human genomic data and the infrastructure and technologies that support these collections as national strategic resources (NSR). As a result, their curation, cultivation, and protection are no longer viewed as just supportive of biomedical research and innovation, but as a critical concern of national security, economic security, and national autonomy. Strategic resource essentially denotes any resource for which states compete and is necessary to effectuate a national strategic goal.<sup>10</sup> Although sharing genomic data is mutually beneficial, states may still seek to exclude foreign researchers, research institutions, and

## Preserving the genomic commons and its substantial benefits for the international research and healthcare communities requires further analysis of the legal consequences and ethical implications of policies that categorize genomic data as a national strategic resource.

commercial entities from accessing genomic data to secure a competitive advantage through asymmetric access to information.<sup>11</sup> Alternatively, states may seek to exclude foreign governments from accessing data to prevent their misuse as a weapon or surveillance tool.<sup>12</sup> These policies threaten to undermine the basic reciprocity that underscores the genomic commons, and elevate national interests over collective interests in biomedical advancement.

Preserving the genomic commons and its substantial benefits for the international research and healthcare communities requires further analysis of the legal consequences and ethical implications of policies that categorize genomic data as a national strategic resource. We will begin in Part I by providing a definition and overview of the genomic commons and highlight some ongoing developments in the commons. Next, we will identify recent policy developments in China, the US, and the EU that demonstrate how these jurisdictions increasingly categorize human genomic data as a NSR (Part II). We then explore the implications these new developments may have for important aspects of the genomic commons including international collaboration, shared infrastructure, and shared ethical safeguards and oversight (Part III).

Finally, we will conclude with some brief recommendations for future research with the goal of empowering the international research community to respond to genomic data as a NSR.

### I. Definition and Overview of the Genomic Commons

There is no commonly accepted definition for the genomic commons, but we will largely build off the concept outlined by Contreras and Knoppers.<sup>13</sup> When we refer to the genomic commons (“*the commons*”), we refer specifically to the global collection of human genomic data — including sequenced data, association data, and phenotypic data — housed in a variety of public and private databases, available for shared use and access, and subject to common rules and governance.<sup>14</sup> This commons originated with the policies surrounding the Human Genome Project and subsequent Bermuda principles, which required the rapid and public release of sequenced genomic data.<sup>15</sup> Since then *the commons* has evolved through polycentric compromise and negotiation into a global system encompassing a diverse set of stakeholders and increasingly complex collections of health and genomic data.<sup>16</sup> A full exploration of *the commons* is beyond the scope of this paper, but here we highlight some ongoing developments in *the commons* that are important to understanding genomic data as a NSR.

First, genomic data accessible in *the commons* are not kept in isolation, and are increasingly integrated with routinely collected personal health data leading to what some have termed a medical information commons.<sup>17</sup> This has been driven in a large part by the demands of studies that utilize advanced statistical methods and require large amounts of phenotypic data like Genome Wide Association Studies (GWAS) and phenome-wide association studies (PheWAS).<sup>18</sup> Recognizing the need for more data, policymakers have sought to accelerate integration through large publicly funded precision medicine initiatives and databases like the the All of Us Research Program in the US.<sup>19</sup> There are also ongoing efforts to make electronic health records more available for secondary research purposes along with genomic data. An example of this is the recently proposed EU regulation for a European Health Data Space (EHDS).<sup>20</sup>

Second, of equal importance to open access policies that support *the commons* is the information technology (IT) infrastructure that supports the secure access,

storage, and sharing of genomic data on a global scale. This includes databases, federated networks, cloud service providers, data management platforms, and software providers that are essential for analyzing ever larger volumes of health and genomic data<sup>21</sup> and overcoming issues regarding data silos and interoperability.<sup>22</sup> The provision of this infrastructure is also the focus of some large initiatives sponsored by governments, public funding agencies, and non-profit institutions including the Global Alliance for Genomics and Health (GA4GH),<sup>23</sup> the European 1+ Million Genomes Initiative,<sup>24</sup> and the China National GeneBank DataBase (CNCBdb).<sup>25</sup>

Third, although *the commons* is by definition a public resource, private commercial organizations play an important and increasingly essential role as sources of data, expertise, innovation, and infrastructure in genomics research.<sup>26</sup> This is especially true regarding the direct-to-consumer (DTC) genetic testing industry and cloud computing industries. For example, 23andMe, a US based for-profit corporation that offers DNA testing for health and ancestry purposes, has amassed a genomic database of at least one million individuals and its research team has made valuable contributions to genomics research in recent years.<sup>27</sup> Moreover, as genomics research becomes more reliant on computing power, more research involves public-private partnerships between research institutions and commercial providers of cloud computing and data analysis services.<sup>28</sup> Some examples include Amazon Web Services (AWS),<sup>29</sup> Microsoft Azure,<sup>30</sup> and Google Cloud.<sup>31</sup> As a result, a broad range of policies targeting private and public sector organizations that collect genomic data or provide computing services could impact data sharing in *the commons*.

## II. Genomic Data as a National Strategic Resource

As previously stated, a NSR is essentially any resource for which states compete and is necessary to effectuate a national strategic goal. It can also be thought of as the stock of national resources which states can depend on when there is an unexpected surge of demand such as for medical supplies during a pandemic, food reserves during a drought, and natural gas during a foreign conflict.<sup>32</sup> Large collections of data have been recognized as fundamental strategic resources needed to develop new technologies, compete economically and militarily, and improve public services.<sup>33</sup>

We use the term NSR in this context to emphasize several common features among policies, which we refer to as NSR Policies, that are markedly different than policies that have supported the creation of *the*

*commons* over the past several decades. First, NSR policies primarily serve a strategic purpose rather than a purpose in support of human rights or values. Second, NSR policies serve to protect, acquire, or restrict the use of genomic data as a collective resource rather than as a vested personal privacy or data protection right. That is to say data protection or privacy are not the exclusive objective of these policies even if there may be some benefits to data protection or privacy. Third, NSR policies tend to treat control over genomic data as a competition or zero-sum game rather than a cooperative endeavor based on reciprocity, like *the commons*. As such NSR policies are those that tend to dispose of the benefits of global cooperative biomedical research and innovation in favor of strategic benefits, the interests of a limited set of countries, or explicitly national interests. States may accomplish this by restricting access or granting preferential access to certain categories of data, specific data sources, or data infrastructure.

### 1. China: Human Genetic Resources and Biosecurity

Of the three jurisdictions we will highlight, China has been the most consistent and assertive in characterizing human genomic data as a national resource, but it has not always done so in a way targeted towards exclusion. As far back as 1998 the Ministry of Science and Technology (MOST) has enforced its *Interim Measures*, which were essentially licensing restrictions on the export of so called “human genetic resources” (HGR), including *inter alia* genomic data.<sup>34</sup> These measures required foreign entities to obtain a permit, register with local authorities, and collaborate with a Chinese institution to access Chinese HGR.<sup>35</sup>

Facially, the *Interim Measures* are at odds with data sharing principles supporting *the commons* and mostly seem to be an obstacle to international collaboration,<sup>36</sup> but some context is needed. The original purpose of these measures was to prevent biopiracy, or uncompensated exploitation of a country’s genetic resources, and to ensure that as a developing country China received its fair share of the benefits that might accrue from Chinese HGR.<sup>37</sup> Rather than discourage collaboration, the number of international collaborations between Chinese institutions and institutions in developed countries rose dramatically during the 2000s.<sup>38</sup> Indeed, for the most part the *Interim Measures* seem to have been interpreted narrowly or lightly enforced in this context.

Since 2016, coinciding with Xi Jinping’s administration, it has become increasingly clear that Chinese officials view the collection and exclusive control of genomic data as critical to economic development and

national security.<sup>39</sup> The Chinese government has stated an intent to become a world leader in the fields of biotechnology and precision medicine and has recognized the need for large amounts of health and genomic data to achieve this goal.<sup>40</sup> It has facilitated this through the mass collection of health and genomic data at home and abroad through publicly funded development of data infrastructure, largescale sequencing initiatives, and investment in private genomics companies.<sup>41</sup>

In late 2018, for the first time Chinese officials publicly denounced five Chinese institutions for violating the data export requirements in the *Interim Measures*.<sup>42</sup> These companies included the BGI group, which had published the results of a large international study on the genetics of depression in *Nature*<sup>43</sup> without MOST's permission.<sup>44</sup> Following this, in early 2019 China enacted its first comprehensive regulation on HGR, the Regulation on the Management of Human Genetic Resources (MHGR), and in 2020 it enacted a first of its kind Biosecurity Law, with strict sets of provisions directly addressing HGR used in research and international collaboration.

The MHGR and Biosecurity Law together form the backbone of the new Chinese legal regime for human genomic data. The MHGR mostly codified many of the requirements of the *Interim Measures* while adding stricter controls on foreign researchers.<sup>45</sup> The Biosecurity law imposed a new governance framework for managing seven identified biology related activities that present national security risks, including the management of HGR.<sup>46</sup> Recognizing the complex interaction between these two laws, in March 2022 MOST released a set of draft implementing rules that represent a substantial break from policies underscoring the commons. They effectively ban the provision, use, or collection of HGR information by foreign controlled entities.<sup>47</sup> All international research collaborations involving HGR must share a backup of any HGR data with Chinese researchers and the Chinese government.<sup>48</sup> Moreover, the laws require a MOST security review for the foreign provision of HGR of important biological families, HGR originating from sensitive places, exome sequencing and genome sequencing of over 500 individuals, and any other cases that could impact public health, national security, or the social interests of the state.<sup>49</sup> There is some dispute over the full impact of the provisions, particularly as Chinese researchers continue to share research data even in the face of suspected government pressure.<sup>50</sup> Nevertheless, there is already some evidence that these laws are having a chilling effect on international collaborations with Chinese researchers.<sup>51</sup> There are also examples of recent retractions of genomic data linked

to international publications at the request of Chinese institutions.<sup>52</sup>

## 2. *The United States: Research Integrity and Safeguarding the Bioeconomy*

For the US, treating genomic data as a NSR stands in contrast to the past commitment and continued leadership of US institutions in promoting the genomic commons. From their inception with the polices surrounding the HGP and continuing to this day, open access and widespread genomic data sharing are the official policy of US funding institutions, like the National Institutes of Health (NIH),<sup>53</sup> and reinforced by funding legislation, like the 21<sup>st</sup>

Century Cures Act.<sup>54</sup> Moreover, while the EU, China, and most countries around the world have gradually adopted stricter data localization measures and controls on international data sharing, the main US federal laws that regulate genomic data sharing in this context, namely the Health Insurance Portability and Accountability Act (HIPAA) and the human subjects research protections found in *the Common Rule*, impose few restrictions on international data sharing.<sup>55</sup>

The characterization of genomic data as a national strategic resource in the US can be largely attributed to its geopolitical rivalry with China. Since 2017, US intelligence agencies have raised national security concerns related to Chinese access to genomic data through scientific collaboration, funding of scientific research, investment in US genomic sequencing companies, and the purchase of US companies.<sup>56</sup> The first two concerns prompted a series of investigations related to research security including a 2018 report by the Office of the Inspector General (OIG) of the Department of Health and Human Services (HHS) that addressed the potential national security risks of foreign access to genomic data.<sup>57</sup> They have also led to NIH investigations and the controversial Department of Justice (DOJ) investigation of foreign researchers known as the China Initiative.<sup>58</sup> Although these investigations have been discontinued, they caused many institutions to reassess foreign collaborations and may have a chilling effect on collaborations moving forward.<sup>59</sup>

The most forceful policy responses have been targeted towards concerns related to Chinese access to genomic and health data through investment and partnerships with US based private sector organizations. These concerns relate to Chinese government access to sensitive health and genetic data and its impact on US national security and economic competitiveness in the bioeconomy.<sup>60</sup> The national security threat from

Chinese access to sensitive data is more straightforward: US officials fear that certain sensitive data could compromise important individuals, like government officials, or reveal strategic vulnerabilities regarding the US population.<sup>61</sup> The economic security threat regarding data access and competitiveness in the bioeconomy is described in the 2019 report *Safeguarding the bioeconomy* from the National Academies of Sciences, Engineering, and Medicine.<sup>62</sup> Billions in public research expenditures, free access to genomics data held in the *commons*, public-private partnerships, and private venture capital investment form a complex ecosystem that drives health innovation.<sup>63</sup> As such, large collections of genomic data held by public organizations and increasingly private consumer genomics companies are a critical input for technological advancement in key areas like the development of pharmaceuticals and managing public health.<sup>64</sup> The fear that the report focuses on is foreign government aligned organizations receiving asymmetric access to genomic data generated by US firms and research organizations.<sup>65</sup> A situation which could lead to a loss of economic competitiveness in strategic health sectors and create strategic vulnerabilities for the US.

Though some of these concerns could be mitigated through data protection legislation, it is telling that the US has instead responded through national security laws and policies. Through legislation like the Foreign Investment Risk Review Modernization Act (FIRRMA) in 2018<sup>66</sup> and various executive orders,<sup>67</sup> the Federal government has endowed executive agencies with increased authority to intervene in transactions that involve foreign organizations and US health and genomic data. For instance, in 2019 the Committee on Foreign Investment in the United States (CFIUS) used its new authority under FIRRMA to compel iCarbonX, a Chinese genomics company, to divest its controlling stake in PatientsLikeMe, a US based personalized health research company.<sup>67</sup> The purpose of the deal was to combine PatientsLikeMe health data, a network of 500,000 individuals, with iCarbonX's genomics and AI technology to drive new health research and treatment.<sup>68</sup> Although CFIUS orders are not published (for national security purposes), the deal was likely blocked out of fear that the Chinese government would be able to access the sensitive health data of US persons.<sup>69</sup>

More recently in late 2021, the Department of Commerce (DOC) issued a new interim rule (the Supply Chain Rule).<sup>70</sup> This rule originates from an executive order of June 2021, the *Executive Order on Protecting Americans' Sensitive Data from Foreign Adversaries*, in which the Biden administration ordered HHS and

the DOC to evaluate and respond to the threat of Chinese access to large repositories of sensitive US health and genetic data and its impact on US national security and economic interests.<sup>71</sup> This rule authorizes the DOC to intervene in or prohibit any transaction of information services or technology between a US person and a foreign controlled entity that involves the transfer or collection of large amounts of sensitive US health or genetic data and that threatens national security.<sup>72</sup> Given its sheer breadth, this rule could enable DOC intervention in a wide range of scenarios, including a research center contracting with a foreign cloud service provider, a partnership between a US hospital and a foreign genomics institute, or a research lab licensing software developed by a foreign entity.

### 3. The European Union: Digital Sovereignty and Strategic Autonomy

Like the US, the EU has generally been a leader in genomic data sharing and open science initiatives, and it continues to advocate for these policies today. The EU has also long been a world leader in setting data protection standards for sensitive data like genetic data.<sup>73</sup> Most notably since 2018, the EU's General Data Protection Regulation (GDPR) has imposed strict rules on the processing of large-scale sensitive data including genetic data.<sup>74</sup> The main objective of the GDPR is to protect the fundamental rights of individuals and is therefore not an NSR policy. However, it is worth mentioning here because of its central role in EU law and policies and the challenges it has presented for *the commons* and international transfers of biomedical research data.<sup>75</sup>

For the EU, the characterization of genomic data as a NSR has been an indirect result of its push to leverage EU data in healthcare and health innovation in the post-GDPR era. This push has centered around strategic autonomy, which is a term that was first used in the field of defense but has since emerged as a catch-all term for EU industrial policy that aims to increase European autonomy in specific strategic sectors.<sup>76</sup> Digital health has been recognized as one of these strategic sectors and the EU hopes to achieve strategic autonomy in this sector by unleashing its Strategy for Data.<sup>77</sup> The Strategy for Data is not one policy, but rather several pieces of legislation aimed at harnessing data as an economic resource that can help the EU maintain a competitive edge in strategic sectors.<sup>78</sup> This strategy represents a clear shift from the individual rights framework of the GDPR to policies that represent broader strategic and economic concerns associated with data.

Understanding how Strategy for Data legislation treats genomic data as an NSR requires some brief background on the international transfer regime for personal data under the GDPR. Under the GDPR and the Court of Justice of the European Union (CJEU) case law, personal data may only be transferred to a third country if provided a level of technical or legal protection that is essentially equivalent to that in the EU.<sup>79</sup> The European Commission can determine that a jurisdiction provides adequate legal protections, subject to certain conditions, and render an adequacy decision for that jurisdiction under Article 45.<sup>80</sup> Alternatively, data exporters can make an individual determination that, subject to certain contractual and technical safeguards, a transfer will provide essentially equivalent protections and rely on several other possible transfer mechanisms under Articles 45 or 46.<sup>81</sup> Adequacy decisions provide exporters with the most certainty, but thus far have only been rendered for a very limited number of countries. A list which does not include the US after the CJEU invalidated the Commission's partial adequacy decision for the US-EU Privacy Shield agreement due to concerns about the surveillance practices of US intelligence agencies in *Data Protection Commissioner v Facebook Ireland Limited and Maximillian Schrems (Schrems II)*.<sup>82</sup> There are ongoing efforts to render a new adequacy decision under the 2022 Trans-Atlantic Data Privacy Framework,<sup>83</sup> but these are not guaranteed to survive judicial scrutiny. Meanwhile, the alternatives to an adequacy decision have also generated a great deal of uncertainty and the required individual analysis may prove costly and risky for many health data exporters, especially researchers.<sup>84</sup>

The Strategy for Data legislation, including the recently passed Data Governance Act (DGA) and proposals like the EHDS proposal, could have provided a solution to the obstacles GDPR has created for international data sharing. Instead, these proposals appear to have created a new maze of restrictions on the international transfer of non-personal data that mirrors the adequacy system under the GDPR.<sup>85</sup> For instance, the EHDS proposal requires data users and access bodies to implement legal and organizational measures to prevent the international transfer or foreign government access to non-personal electronic health data.<sup>86</sup> This works conjointly with Article 5 of the DGA which allows the Commission to adopt delegated acts that implement special conditions for the international transfer of public sector data deemed highly sensitive, which according to the DGA includes many health and genomic data.<sup>87</sup>

On one hand, these restrictions could be justified in part by individual rights' concerns, more specifi-

cally a residual risk of anonymized data being subject to reidentification in some cases. Both the EHDS proposal and the DGA offer this reidentification risk as one justification for these further restrictions on transfers of non-personal data.<sup>88</sup> On the other hand, as some have already pointed out, adding an additional adequacy assessment on top of GDPR requirements and new security requirements in the EHDS is not necessarily justified from a privacy or data protection standpoint.<sup>89</sup> The EHDS and DGA also explicitly present economic concerns as a justification for these policies, specifically the issue of non-personal data revealing trade secrets or commercially sensitive information.<sup>90</sup> This comports more with the economic competitiveness concerns that European officials have frequently emphasized in the context of the Strategy for Data, namely issues with relying on foreign providers and improving EU digital competitiveness.<sup>91</sup>

Other EU laws associated with the Strategy for Data also put in place policies that, though perhaps justified through fundamental rights arguments, seem to serve more of an economic protectionist purpose. For example, the draft European Union Cybersecurity Certification Scheme for Cloud Services (EUCCS) reportedly will require cloud service operators to maintain cloud service operations and store data solely within the EU to receive the highest level of certification.<sup>92</sup> Although this certification scheme is supposedly voluntary, given the particular sensitivity of health and genomic data, many believe it would effectively become mandatory for many businesses and institutions.<sup>93</sup> Some have called for EU based storage of health and genetic data as a necessary precaution against data protection and privacy risks.<sup>94</sup> Others have, however, pointed out that these measures seem to suggest that non-European access to data should always be avoided without regard for a third party country's particular safeguards or reasons for accessing data.<sup>95</sup> The EU has also repeatedly made it clear that is actively concerned about the connection between control over data and control over critical data infrastructure.<sup>96</sup>

### III. Implications for the Genomic Commons

#### 1. Open Access Policies and International Data Sharing

Policies that categorize genomic data as a NSR are likely to create additional obstacles to open access and international data sharing, which in turn will impact the amount of genomic data accessible in *the commons*. One of the main challenges facing *the commons* in the past decade has been balancing the desire for widespread data sharing with data protection requirements and security concerns.<sup>97</sup> New NSR policies will

add additional hurdles for transferring personal and non-personal data to *the commons*, and new national strategic considerations to balance along with privacy concerns. The impact will be most tangible in China where international collaborations and publishing the results of studies involving Chinese HGR will at a minimum require a more time consuming and complicated application process,<sup>98</sup> in which officials may be guided by economic protectionist mindsets or changing political considerations. New restrictions on the transfer of non-personal data under Strategy for Data legislation could also complicate transfers

some results will not be publishable, a situation that may in many cases conflict with statutory requirements or requirements in grants.

As a result of these new restrictions on data transfers, the genomic commons may fracture into smaller international commons. This might be motivated by larger geopolitical concerns that make it easier to cooperate with one country rather than another. Countries may be forced to pick sides among global powers, effectively choosing among smaller research commons under EU standards, US standards, or Chinese standards. As China and the US race for technologi-

**Policies that categorize genomic data as a NSR are likely to create additional obstacles to open access and international data sharing, which in turn will impact the amount of genomic data accessible in the commons. One of the main challenges facing the Commons in the past decade has been balancing the desire for widespread data sharing with data protection requirements and security concerns**

of data for health research as has been the case with the GDPR.<sup>99</sup> For instance, requirements under the EHDS may make it hard to transfer even de-identified summary statistics derived from genomic data found in EU electronic health records or made available by data access committees.

A more invidious obstacle might come in the form of opaque security reviews under emerging regimes in China and the US. In both cases, these reviews leave enormous discretion to national governments to determine what is considered a national security threat, to allow retroactive state action with little warning,<sup>100</sup> and may be unreviewable by a national tribunal.<sup>101</sup> There is a high probability that these reviews may be perceived as arbitrary or discriminatory, as was the case when the Trump administration took action against a number of Chinese technology companies with sparse reasoning.<sup>102</sup> Such action might also be politically motivated, such as China censoring scientific data surrounding the origins of Covid-19.<sup>103</sup> Researchers may be reluctant to share data with foreign researchers that are not providing reciprocal access or in situations that may provoke a government investigation. These policies could also reduce innovative partnerships between private companies and cut researchers off from valuable new forms of research data. Alternatively, some researchers may avoid working on international collaborations out of fear that

cal supremacy in genomics and personalized health,<sup>104</sup> this could raise the stakes of collaboration. It could also create difficult dilemmas for many researchers, especially given the pressing need for larger and more diverse genomic and health data sets for health equity and biomedical advancement.<sup>105</sup>

This fracturing of the commons is likely to have a disproportionate impact on poor and developing countries. For wealthy democracies like Canada, the United Kingdom, and Japan with close strategic ties, adequacy agreements, and strong institutional ties, data-sharing and collaboration will continue basically as usual. China may find itself excluded from some international genomics sharing and collaborations, but it is also a well-resourced and highly integrated part of the global research community.<sup>106</sup> Poor countries and developing countries may have neither the privileged strategic relationships of wealthy countries nor the domestic resources of China. As such, they may be viewed less as allies from a national strategic perspective and become more reliant on partnering with larger developed countries for biomedical research. There are some notable initiatives in understudied areas of the world like Africa<sup>107</sup> and Southeast Asia<sup>108</sup> to scale up genomics research, but these initiatives would still benefit from the resources and expertise of the global genomics community.<sup>109</sup> While the global research community has recognized the need to



be more inclusive in genomics research, governments may not share this sentiment particularly where there are security concerns.<sup>110</sup>

### 2. Shared Infrastructure and Information Security

Another area likely to be impacted by genomic data as a NSR is the provision of shared technical infrastructure. Shared infrastructure is necessary for interoperability and secure data sharing and has been a central policy issue for advocates of *the commons*.<sup>111</sup> Much progress has been made in recent years and more advancements are on the horizon, but new NSR policies could further complicate public and private initiatives.

First, governments may view foreign infrastructure as a means to gain access to data and therefore consider it a national security risk and seek to ban it altogether. US reports especially indicate concerns that foreign adversaries may use IT infrastructure and software to acquire sensitive US health and genetic data.<sup>112</sup>

industries by presenting them as safer or more reliable than foreign services.

At a minimum, self-preferential policies could undermine the expectations of reciprocity that are essential to maintaining *the commons*. These policies could also cut off researchers in one country from access to the best technologies in another. For instance, due to US dominance in cloud computing and other technology increasingly relevant to health research like mobile devices, EU member states have few competitive domestic alternatives.<sup>113</sup> Attempts to foster domestic industries as substitutes in data driven and high-tech industries are far from guaranteed to be successful.<sup>114</sup>

### 3. Risk Assessments and Research Ethics

Genomic data as a NSR could fracture many of the shared research ethics and data governance principles of *the commons* such as *objectivity, fairness and transparency*.<sup>115</sup> More specifically, it raises concerns

**Concerns about misuse, nationalistic ideals, and pressure from state funding agencies may complicate the calculus when researchers and ethics committees are weighing the potential benefits and risk of collaboration and data-sharing. An ex post facto public revelation of foreign misuse of research data could have a deleterious impact on public trust in any research institutions involved. Studies have shown that risks of data leakage and fear of misuse are decisive factors in individual willingness to participate in biobanking and to contribute data for social welfare purposes.**

They suggest that either due to national security provisions under Chinese law or direct involvement through state-owned businesses the Chinese government could access genomic data and use it for its own purposes. Conflicting bans on the use of foreign infrastructure may prevent foreign research institutions from collaborating on large data sets in any meaningful way. It may also discourage collaboration on projects that involve advanced computing methods or technology.

Second, governments may pass laws or create funding incentives for economic purposes that lead researchers to rely exclusively on domestic infrastructure. Essentially, governments may put in place protectionist measures to ensure that domestic infrastructure providers or domestic technology providers have access to more health or genomic data or preferential access to data relative to foreign competitors. Even if they do not do so directly, policies like the EUCS might still offer an indirect boost to domestic

that national security agencies and policy makers with national strategic interests in mind will have an undue influence on researchers or data access governance. Ethical frameworks vary from country to country, but prevailing international norms emphasize the importance of voluntariness for participation in human subjects research and the need for researchers to weigh the risks and benefits of research.<sup>116</sup> Governments, as the primary funders of research, can either directly or indirectly create improper incentives for researchers and research institutions. A series of ethical violations by the US government during the post world two era, including harmful radiation testing on human subjects, show a serious tension between research ethics rules and national security interests shrouded in secrecy.<sup>117</sup> There are also fears that Chinese laws may carve out too large an exception for the state that undermines the independence of researchers and research institutions.<sup>118</sup>

NSR policies might also lead to fears that data may be weaponized or used as a surveillance tool by either foreign or domestic governments. No country has an official public policy towards weaponizing genomic data per se, but there are concerning reports of activities in China. In one well documented incident, the BGI group, a state-owned Chinese life sciences and genomics research conglomerate, was using health and genetic data collected from non-invasive prenatal genetic test kits to conduct population studies with the Peoples Liberation Army (PLA).<sup>119</sup> These kits were used by millions of individuals around the world, in EU members states, the United Kingdom, Canada, and Australia.<sup>120</sup> Though Chinese officials deny that any non-Chinese national data was used in this research, there were concerns that the “terms of use” associated with these tests would have allowed it anyway.<sup>121</sup> There is also evidence of Chinese researchers publishing a disproportionately high number of studies on the genetic characteristics of minority populations like the Uighurs and Tibetans. Many of these studies have been redacted for ethical reasons and raise alarming implications regarding the use of publicly accessible genomic data for surveillance purposes.<sup>122</sup> Such revelations may further cast doubt on the authenticity or quality of foreign ethics reviews.

In either case, concerns about misuse, nationalistic ideals, and pressure from state funding agencies may complicate the calculus when researchers and ethics committees are weighing the potential benefits and risk of collaboration and data-sharing. An ex post facto public revelation of foreign misuse of research data could have a deleterious impact on public trust in any research institutions involved. Studies have shown that risks of data leakage and fear of misuse are decisive factors in individual willingness to participate in biobanking and to contribute data for social welfare purposes.<sup>123</sup> This raises difficult questions about whether risks like state-backed data theft and foreign misuse ought to be disclosed to research participants. Some researchers may feel that these risks are remote, as was the case in the US when researchers pushed back against a congressional proposal for national security requirements for genomic data.<sup>124</sup> Nevertheless, it may be an important consideration for some research subjects and therefore relevant to disclose during the informed consent process.

#### IV. Future Research and Concluding Remarks

By many accounts, the genomic commons has been a highly impactful and successful system of governing and harnessing human genomic data for biomedical

advancement.<sup>125</sup> The governance structure of *the commons* can accommodate laws and policies that further some national interests like those related to data protection, individual and collective privacy rights, and fairness between countries. However, policies that categorize genomic data as a NSR threaten to undermine the careful balancing and basic reciprocity needed to facilitate an international collaborative endeavor like *the commons*. As such, the international research community should prepare to respond to these policies with further research in four areas.

First, other areas of scientific research, including some in the biological sciences, are more carefully controlled by governments for national strategic purposes and might serve as a model moving forward. A good example here is the closely related Nagoya protocol, which provides for equitable access and benefit sharing for non-human genetic resources, while recognizing sovereignty over domestic genetic resources.<sup>127</sup> Some suggest that employing these types of policies for human genomic data might even improve international data sharing.<sup>128</sup>

Second, stakeholders need to further explore the impact of NSR laws and policies on international collaboration. This is especially critical for laws and policies that might fall outside the typical expertise of the biomedical research community. As genomics research involves more public-private partnerships and leverages new forms of technology, policies that restrict foreign IT infrastructure, computing, and AI technology could have a substantial impact on international collaboration in genomics research.

Third, policies in countries outside of the three jurisdictions discussed here ought to be examined as well. For instance, Australia and the United Kingdom have close strategic ties with the US and EU and they have raised some concerns about foreign access to research data.<sup>129</sup> Alternatively, various middle income and developing countries may have strict restrictions on the export of human genomic data for national strategic reasons that are different than those examined in this paper. Closer attention ought to be paid to these laws, as well as the impact of new data or infrastructure restrictions on middle income and developing countries. This is especially important considering the potential impact of laws and policies on recent efforts to increase diversity and equity in genomics research.

Finally, stakeholders need more information and guidelines to respond to NSR policies. Not everyone agrees on the gravity of national security risks or on the wisdom of localizing data or preferencing domestic infrastructure. Stakeholders armed with data and research that shows the impact of NSR policies on sci-

entific objectives might have more success influencing national policy makers. Regardless, genomic data as an NSR is likely to be the new norm and something that the international research community will need to continually respond to moving forward.

### Acknowledgements

This work has been supported by the funding from FWO Flanders-Quebec grant.

### References

- J.L. Contreras and B.M. Knoppers, "The Genomic Commons," *Annual Review of Genomics and Human Genetics* 19 (2018): 429–453, <https://doi.org/10.1146/annurev-genom-083117-021552>.
- L. Hood and L. Rowen, "The Human Genome Project: Big Science Transforms Biology and Medicine," *Genome Medicine* 5, no. 79 (2013): 1–8, <https://doi.org/10.1186/gm483>.
- R. Cook-Deegan, R.A. Ankeny, and K.M. Jones, "Sharing Data to Build a Medical Information Commons: From Bermuda to the Global Alliance," *Annual Review of Genomics and Human Genetics* 18 (2017): 389–415, <https://doi.org/10.1146/annurev-genom-083115-022515>.
- M. Phillips and B.M. Knoppers, "Whose Commons? Data Protection as a Legal Limit of Open Science," *Journal of Law, Medicine & Ethics* 47 (2019): 106–111, <https://doi.org/10.1177/1073110519840489>; K. Powell, News Feature, "The Broken Promise That Undermines Human Genome Research," *Nature* 590 (2021): 198–201, <https://doi.org/10.1038/d41586-021-00331-5>.
- See Powell, *supra* note 4; see also G. Gürsoy, "Criticality of Data Sharing in Genomic Research and Public Views of Genomic Data Sharing," in *Responsible Genomic Data Sharing*, eds. X. Jiang and H. Tang (New York: Academic Press, 2020): 3–18, <https://doi.org/10.1016/B978-0-12-816197-5.00001-2>.
- See E.D. Green, C. Gunter, L.G. Biesecker, et al., "Strategic Vision for Improving Human Health at The Forefront of Genomics," *Nature* 586 (2020): 683–692, <https://doi.org/10.1038/s41586-020-2817-4>.
- S. Scollen et al., "From the Data on Many, Precision Medicine for 'One': The Case for Widespread Genomic Data Sharing," *Biomedicine Hub* 2, Suppl. 1 (2017): 1–7, <https://doi.org/10.1159/000481682>.
- See S.M. Kissler et al., "Viral Dynamics of SARS-CoV-2 Variants in Vaccinated and Unvaccinated Persons," *New England Journal of Medicine* 385, no. 26 (2021): 2489–2491, <https://doi.org/10.1056/NEJMc210250>; S. Knyazev, K. Chhugani, V. Sarwal, et al., "Unlocking Capacities of Genomics for the COVID-19 Response and Future Pandemics," *Nature Methods* 19 (April 2022): 374–380, <https://doi.org/10.1038/s41592-022-01444-z>; M.C. Roberts, A.E. Fohner, L. Landry, et al., "Advancing Precision Public Health Using Human Genomics: Examples from the Field and Future Research Opportunities," *Genome Medicine* 13, no. 97 (June 2021): 1–10, <https://doi.org/10.1186/s13073-021-00911-0>.
- A.R. Bentley, S. Callier, and C.N. Rotimi, "Diversity and Inclusion in Genomic Research: Why the Uneven Progress?" *Journal of Community Genetics* 8 (October 2017): 255–66 <https://doi.org/10.1007/s12687-017-0316-6>.
- R.J. Beber, "Treating Information as a Strategic Resource to Win the 'Information War,'" *Orbis* 61 (2017): 394–403, <https://doi.org/10.1016/j.orbis.2017.05.007>.
- M. Berger and P.A. Schneck, "National and Transnational Security Implications of Asymmetric Access to and Use of Biological Data," *Frontiers in Bioengineering and Biotechnology* 7, no. 21 (2019): 1–7, <https://doi.org/10.3389/fbioe.2019.00021>.
- Id.*
- Contreras and Knoppers, *supra* note 1.
- Id.*
- K.M. Jones, R.A. Ankeny, and R. Cook-Deegan, "The Bermuda Triangle: The Pragmatics, Policies, and Principles for Data Sharing in the History of the Human Genome Project," *Journal of the History of Biology* 51 (2018): 693–805, <https://doi.org/10.1007/s10739-018-9538-7>.
- Contreras and Knoppers, *supra* note 1.
- Cook-Deegan, Ankeny, and Jones, *supra* note 3; see also Contreras and Knoppers, *supra* note 1, at 446.
- H. Daniels et al., "Exploring the Use of Genomic and Routinely Collected Data: Narrative Literature Review and Interview Study," *Journal of Medical Internet Research* 23, no. 9 (2021): e15739, <https://doi.org/10.2196/15739>.
- The All of Us Research Program Investigators, "The 'All of Us' Research Program," *New England Journal of Medicine* 381 (2019): 668–76 (Hereinafter "All of Us"), <https://doi.org/10.1056/NEJMs1809937>.
- Proposal for a Regulation of the European Parliament and of The Council on the European Health Data Space COM (2022) 197 (hereinafter 'EHDS Proposal'), at Art. 1.
- R. Krishna and V. Elisseev, mini review, "User-Centric Genomics Infrastructure: Trends and Technologies" *Genome* 64 (2020): 467–75, <https://doi.org/10.1139/gen-2020-0096>.
- R. Asiimwe et al., "From Biobank and Data silos into a Data Commons: Convergence to Support Translational Medicine" *Journal of Translational Medicine* 19, no. 493 (2021): 1–13, <https://doi.org/10.1186/s12967-021-03147-z>.
- H.L. Rehm et al., "GA4GH: International Policies and Standards for Data Sharing across Genomic Research and Healthcare," *Cell Genomics* 1, no. 100029 (2021): 1–33, <https://doi.org/10.1016/j.xgen.2021.100029>.
- G. Saunders et al., "Leveraging European Infrastructures to Access 1 Million Human Genomes by 2022," *Nature Reviews* 20 (2019): 693–701, <https://doi.org/10.1038/s41576-019-0156-9>.
- F. Z. Chen et al., "CNCBdb: China National GeneBank Database," *Yi Chuan = Hereditas* 42 (2020): 799–809, <https://doi.org/10.16288/j.ycz.20-080>.
- National Academies of Sciences, Engineering, and Medicine, *Safeguarding the Bioeconomy* (Washington, DC: The National Academies Press 2020) (hereinafter "Safeguarding the Bioeconomy"), at 206–12, <https://doi.org/10.17226/25525>.
- 23andMe, *Publications*, available at <<https://research.23andme.com/publications/>> (last accessed Jan. 23 2023); 23andMe, *23andMe Publication Dataset Access Program*, available at <[https://research.23andme.com/dataset-access/#how-to;%20https://research.23andme.com/research-innovation-collaborations](https://research.23andme.com/dataset-access/#how-to-%20https://research.23andme.com/research-innovation-collaborations)> (last accessed Jan. 23 2023).
- P.G. Moreno, Y. Joly, and B.M. Knoppers, "Public-Private Partnerships in Cloud-Computing Services in the Context of Genomic Research," *Frontiers in Medicine* 4, no. 3 (2017): 1–15, <https://doi.org/10.3389/fmed.2017.00003>; see e.g. Amazon Web Services, *CHOP Accelerates Pediatric Research Using AWS-Powered Data Resource* (2021), available at <<https://aws.amazon.com/solutions/case-studies/chop>> (last accessed Jan. 23 2023).
- K. Jonakin, *Genomics Data Transfer, Analytics, and Machine Learning using AWS Services*, Amazon Web Services, White Paper (November 2020), available at <<https://aws.amazon.com/blogs/industries/whitepaper-genomics-data-transfer-analytics-and-machine-learning-using-aws-services/>> (last visited May 12, 2023).
- Accelerate Precision Medicine with Microsoft Genomics*, Microsoft Genomics, White Paper (February 2018), available at <<https://azure.microsoft.com/en-us/resources/accelerate-precision-medicine-with-microsoft-genomics/>> (last visited May 12, 2023).
- Google Cloud, *Cloud Life Sciences* (2022) available at <<https://cloud.google.com/life-sciences>> (last visited January 23 2023).

32. P. Paleri, *Revisiting National Security: Prospecting Governance for Human Well-Being* (Singapore: Springer Nature Singapore, 2022), <https://doi.org/10.1007/978-981-16-8293-3>.
33. See Bebbler, *supra* note 10; see also United States Department of Defense, *DoD Data Strategy: Unleashing Data to Advance the National Defense Strategy* (2020) available at <<https://www.defense.gov/News/Releases/Release/Article/2376629/dod-issues-new-data-strategy/>> (last visited May 12, 2023); E. Rosenbach and K. Mansted, *The Geopolitics of Information*, Belfer Center (May 2019), available at <<https://www.hks.harvard.edu/publications/geopolitics-information>> (last visited May 12, 2023).
34. Y. Chen and L. Song, “China: Concurring Regulation of Cross-Border Genomic Data Sharing for Statist Control and Individual Protection,” *Human Genetics* 137 (2018): 605–615, <https://doi.org/10.1007/s00439-018-1903-2>.
35. *Id.*
36. *Id.*
37. Chen and Song, *supra* note 34; see also H. Xue, “Human Genetic Resources, Biopiracy and China’s Response: A Case Study of Harvard-Affiliated Human Genetic Projects in China’s Anhui Province (Part I),” *Journal of International Biotechnology Law* 1 (2004), <https://doi.org/10.1515/jibl.2004.1.5.214>.
38. L. Au and R.G.L. Silva, “Globalizing the Scientific Bandwagon: Trajectories of Precision Medicine in China and Brazil,” *Science, Technology, & Human Values* 46 (2021): 192–225, <https://doi.org/10.1177/0162243920930282>.
39. Y. Lau, *China’s Extensive Use of Genetic Information Sounds a Warning*, Australian Strategic Policy Institute (2022), available at <<https://www.aspistrategist.org.au/chinas-extensive-use-of-genetic-information-sounds-a-warning/>> (last visited May 12, 2023).
40. Gryphon Scientific and Rhodium Group, *China’s Biotechnology Development: The Role of US and Other Foreign Engagement*, a report prepared for the U.S.-China Economic and Security Review Commission (2019), available at <<https://www.uscc.gov/research/chinas-biotechnology-development-role-us-and-other-foreign-engagement>> (last visited May 12, 2023).
41. *Id.* at 117–119.
42. D. Cyranoski, News, “China’s Crackdown on Genetics Breaches Could Deter Data Sharing,” *Nature* 563 (2018): 301–302, <https://doi.org/10.1038/d41586-018-07222-2>.
43. CONVERGE Consortium, “Sparse Whole-Genome Sequencing Identifies Two Loci for Major Depressive Disorder,” *Nature* 523 (2015): 588–91, <https://doi.org/10.1038/nature14659>.
44. Cyranoski, *supra* note 42.
45. W. Li and J. Chen, “Institutional Framework for the Management of Human Genetic Resources in China,” *Human Gene Therapy* 32 (2021): 1495–1500, <https://doi.org/10.1089/hum.2021.096>.
46. L. Huigang et al., “Significance of and Outlook for the Biosafety Law of the People’s Republic of China,” *Journal of Biosafety and Biosecurity* 3 (2021): 46–50, <https://doi.org/10.1016/j.jobbb.2021.06.004>.
47. Implementation Rules for the Regulations on the Management of Human Genetic Resources (Draft for Solicitation of Comments), China Law Translate (CLT) (March 2022), Article 11 and 12, available at <[https://www.chinalawtranslate.com/en/genetics-implementation-draft/#\\_Toc98849216](https://www.chinalawtranslate.com/en/genetics-implementation-draft/#_Toc98849216)> (last visited May 12, 2023), original (Chinese) available at <[https://www.most.gov.cn/tztg/202203/t20220322\\_179904.html](https://www.most.gov.cn/tztg/202203/t20220322_179904.html)> (last visited May 12, 2023).
48. *Id.* at Article 15
49. *Id.* at Article 49.
50. J.Y. Zhang, “To Keep Nationalism in Check, Nurture Science Solidarity,” *Nature* 591 (2021): 9, <https://doi.org/10.1038/d41586-021-00458-5>.
51. J. Cohen, News, “Chinese Researchers Reveal Draft Genome of Virus Implicated in Wuhan Pneumonia Outbreak,” *Science* (2020), <https://www.doi.org/10.1126/science.aba8829>.
52. N. Cai et al., “Retraction Note: 11,670 Whole-Genome Sequences Representative of the Han Chinese Population from the CONVERGE Project,” *Scientific Data* 7, no. 123 (2020), <https://doi.org/10.1038/s41597-020-0430-x>.
53. Final NIH Policy for Data Management and Sharing (DMS Policy) 85 FR 68890 (October 30, 2020) (effective January 25, 2023).
54. M.A. Majumder et al., “Sharing Data under the 21st Century Cures Act,” *Genetics in Medicine* 19 (2017): 1289–94, <https://doi.org/10.1038/gim.2017.59>.
55. M.A. Majumder, “United States: Law and Policy Concerning Transfer of Genomic Data to Third Countries,” *Human Genetics* 137 (2018): 647–55, <https://doi.org/10.1007/s00439-018-1917-9>.
56. Berger and Schneck, *supra* note 11 at 4–5.
57. US Department of Health and Human Services (HHS), Office of the Inspector General (OIG), *Opportunities Exist for the National Institutes of Health To Strengthen Controls in Place To Permit and Monitor Access to Its Sensitive Data*, Report No. A-18-18-09350 (2019).
58. See J. Mervis, News, “U.S. Universities Reassess Collaborations with Foreign Scientists in Wake of NIH Letters,” *Science* (2019) available at <<https://doi.org/10.1126/science.aax8242>> (last visited May 12, 2023); N. Gilbert and M. Kozlov, “The Controversial China Initiative Is Ending — Researchers Are Relieved,” *Nature* 603 (2022): 214–15, <https://doi.org/10.1038/d41586-022-00555-z>.
59. See R. Van Noorden, “The Number of Researchers with Dual US–China Affiliations Is Falling,” *Nature* 606 (2022): 235–236, <https://doi.org/10.1038/d41586-022-01492-7>.
60. The National Counterintelligence and Security Center, *China’s Collection of Genomic and Other Healthcare Data From America: Risks To Privacy And U.S. Economic And National Security* (2021) available at <[https://www.dni.gov/files/NCSC/documents/SafeguardingOurFuture/NCSC\\_China\\_Genomics\\_Fact\\_Sheet\\_2021revision20210203.pdf](https://www.dni.gov/files/NCSC/documents/SafeguardingOurFuture/NCSC_China_Genomics_Fact_Sheet_2021revision20210203.pdf)> (last visited May 12, 2023).
61. *Id.*
62. Safeguarding the Bioeconomy, *supra* note 26 at 206–12.
63. *Id.*
64. *Id.*
65. *Id.*
66. Foreign Investment Risk Review Modernization Act of 2018 (FIRRMA) Pub. Law No. 115-232 tit. XVII §§ 1701-1728.
67. See e.g., Exec. Order 14034, 86 F.R. 31423 (June 11, 2021) (hereinafter “Protecting Americans’ Sensitive Data from Foreign Adversaries”).
68. C. Farr and A. Levy, “The Trump Administration is Forcing this Health Start-up that Took Chinese Money into a Fire Sale,” CNBC, April 4, 2019, available at <<https://www.cnbc.com/2019/04/04/cfius-forces-patientslikeme-into-fire-sale-booting-chinese-investor.html>> (last visited May 12, 2023).
69. *Id.*
70. Securing the Information and Communications Technology and Services Supply Chain; Connected Software Applications 86 F.R. 67379, codified at 15 C.F.R. 7 (November 26, 2021) (hereinafter “Supply Chain Rule”).
71. Protecting Americans’ Sensitive Data from Foreign Adversaries, *supra* note 67.
72. Supply Chain Rule, *supra* note 70.
73. Article 29 Data Protection Working Party Working Document on Genetic Data (17 March 2004) 12178/03/EN WP 91, available at <<https://ec.europa.eu/justice/article-29/documentation/opinion-recommendation/>> (last visited May 12, 2023).
74. Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation: GDPR), O.J. 2016 L. 119/1 (hereinafter “GDPR”) Article 9.
75. See Phillips and Knoppers, *supra* note 4.

76. J. Borrell, High Representative of the European Union for Foreign Affairs and Security Policy / Vice-President of the European Commission, "Why European Strategic Autonomy Matters," (2020) available at <[https://www.eeas.europa.eu/eeas/why-european-strategic-autonomy-matters\\_en](https://www.eeas.europa.eu/eeas/why-european-strategic-autonomy-matters_en)> (last visited May 12, 2023).
77. É. Van den Abeele, *Towards a New Paradigm in Open Strategic Autonomy?* European Trade Union Institute, Working Paper (March 2021), available at <<https://etui.org/publications/towards-new-paradigm-open-strategic-autonomy>> (last visited May 12, 2023).
78. G. Carvalho and E. Kazim, "Themes in Data Strategy: Thematic Analysis of 'A European Strategy for Data' (EC)," *AI and Ethics* 2, no. 1 (2022): 53–63, <https://doi.org/10.1007/s43681-021-00102-y>.
79. See GDPR Recital 104; Judgment of the European Court of Justice of 16 July 2020 in Case C-311/18 (Schrems II); see also D. Hallinan, A. Bernier, A. Cambon-Thomsen et al., "International Transfers of Personal Data for Health Research following Schrems II: A Problem in Need of a Solution" *European Journal of Human Genetics* 29 (2021): 1502–1509, <https://doi.org/10.1038/s41431-021-00893-y>.
80. GDPR Article 45.
81. GDPR Article 46; see Hallinan, Bernier, Cambon-Thomsen et al., *supra* note 79 at 1504–05.
82. Judgment of the European Court of Justice of 16 July 2020 in Case C-311/18 (Schrems II).
83. See *Enhancing Safeguards for United States Signals Intelligence Activities*, Exec. Order 14086, 87 F.R. 62283 (October 14, 2022); *Data Protection Review Court*, 87 F.R. 62303 (October 14, 2022) codified at 28 C.F.R. 201; see also *European Commission and United States Joint Statement on Trans-Atlantic Data Privacy Framework* (22 March 2022) available at <[https://ec.europa.eu/commission/presscorner/detail/nl/ip\\_22\\_2087](https://ec.europa.eu/commission/presscorner/detail/nl/ip_22_2087)> (last visited May 12, 2023).
84. See Hallinan, Bernier, Cambon-Thomsen et al., *supra* note 79.
85. Digital Europe, *Data Transfers in the Data Strategy: Understanding Myth and Reality* (2022), available at <<https://www.digitaleurope.org/resources/data-transfers-in-the-data-strategy-understanding-myth-and-reality/>> (last visited May 12, 2023).
86. EHDS Proposal Articles 33 and 62.
87. Regulation of the European Parliament and of the Council on European data governance and amending Regulation (EU) 2018/1724 (Data Governance Act) O.J. 2018 L. 152 (Hereinafter "DGA") Article 5; EHDS Proposal Art. 61.
88. DGA Article 5; EHDS Article 61.
89. F. Molnár-Gábor, M.J.S. Beauvais, A. Bernier, M.P.N. Jimenez, M. Recuero, and B.M. Knoppers, "Bridging the European Data Sharing Divide in Genomic Science," *Journal of Medical Internet Research* 24, no. 10 (2022): e37236, <https://www.doi.org/10.2196/37236>.
90. EDHS Preamble (64); DGA Article 5; DGA Preamble (15).
91. T. Madiega, *Digital Sovereignty for Europe*, European Parliamentary Research Service ideas paper, PE 651.992 (July 2020) at 4, available at <[https://www.europarl.europa.eu/RegData/etudes/BRIE/2020/651992/EPRS\\_BRI\(2020\)651992\\_EN.pdf](https://www.europarl.europa.eu/RegData/etudes/BRIE/2020/651992/EPRS_BRI(2020)651992_EN.pdf)> (last visited May 12, 2023).
92. Digital Europe, *supra* note 85.
93. *Id.*
94. *EDPB-EDPS Joint Opinion 03/2022 on the Proposal for a Regulation on the European Health Data Space* (12 July 2022) available at <[https://edpb.europa.eu/our-work-tools/our-documents/edpb-edps-joint-opinion/edpb-edps-joint-opinion-032022-proposal\\_en](https://edpb.europa.eu/our-work-tools/our-documents/edpb-edps-joint-opinion/edpb-edps-joint-opinion-032022-proposal_en)> (last visited May 12, 2023).
95. Digital Europe, *supra* note 85.
96. Madiega, *supra* note 91.
97. Phillips and Knoppers, *supra* note 4.
98. S. Mallapaty, News, "China Expands Control over Genetic Data Used in Scientific Research," *Nature* 605 (2022): 405, <https://doi.org/10.1038/d41586-022-01230-z>.
99. H.B. Bentzen et al., "Remove Obstacles to Sharing Health Data with Researchers Outside of the European Union," *Nature Medicine* 27 (2021): 1329–33, <https://doi.org/10.1038/s41591-021-01460-0>.
100. See Cyranoski, *supra* note 42; Farr and Levy, *supra* note 68.
101. The substance of final orders made by CFIUS are not reviewable under 50 U.S.C. § 4565 (e), but they may still be subject to limited review for constitutional due process claims. see *Ralls Corp. v. Committee on Foreign Investment* 758 F.3d 296 (D.C. Cir. 2014).
102. A. Chan, *CFIUS, Team Telecom and China*, Lawfare (Sep. 28 2021) available at <<https://www.lawfareblog.com/cfius-team-telecom-and-china>> (last accessed January 23, 2023).
103. N. Gan, C. Hu, and I. Watson, "Beijing Tightens Grip over Coronavirus Research, amid US-China Row on Virus Origin," *CNN*, April 16, 2020, available at <<https://edition.cnn.com/2020/04/12/asia/china-coronavirus-research-restrictions-intl-hnk/index.html>> (last accessed January 23, 2023).
104. E. Pauwels and A. Vidyarthi, *Who Will Own The Secrets In Our Genes? A U.S. – China Race in Artificial Intelligence and Genomics*, Wilson Center (February 2017), available at <<https://www.wilsoncenter.org/publication/who-will-own-the-secrets-our-genes-us-china-race-artificial-intelligence-and-genomics>> (last accessed January 23, 2023).
105. G. Sirugo, S.M. Williams, and S.A. Tishkoff, "The Missing Diversity in Human Genetic Studies," *Cell* 177 (2019): 26–31, <https://doi.org/10.1016/j.cell.2019.02.048>.
106. J. Johnson, J. Adams, J. Grant, and D. Murphy, *Stumbling Bear, Soaring Dragon Russia, China and the Geopolitics of Global Science*, Kings College Policy Institute (2022), available at <<https://www.kcl.ac.uk/news/universities-must-prepare-for-geopolitical-shock-to-global-research-system-report-warns>> (last accessed January 23, 2023).
107. A. Lumaka et al., "Increasing African Genomic Data Generation and Sharing to Resolve Rare and Undiagnosed Diseases in Africa: A Call-to-Action by the H3Africa Rare Diseases Working Group," *Orphanet Journal of Rare Diseases* 17, no. 230 (2022): 1–6, <https://doi.org/10.1186/s13023-022-02391-w>.
108. GenomeAsia100K Consortium et al., "The GenomeAsia 100K Project Enables Genetic Discoveries across Asia," *Nature* 576 (2019): 106–111, <https://doi.org/10.1038/s41586-019-1793-z>.
109. M. Ramsay, Opinion, "African Genomic Data Sharing and the Struggle for Equitable Benefit," *Patterns* 3, no. 100412 (2022): 1–3, <https://doi.org/10.1016/j.patter.2021.100412>; World Health Organization, *Accelerating Access to Genomics for Global Health: Promotion, Implementation, Collaboration, and Ethical, Legal, and Social Issues* (Geneva: World Health Organization, 2022) available at <<https://apps.who.int/iris/handle/10665/359560>> (last accessed Jan. 23 2023).
110. Zhang, *supra* note 50.
111. Rehm et al., *supra* note 23.
112. Protecting Americans' Sensitive Data from Foreign Adversaries, *supra* note 67.
113. Madiega, *supra* note 96.
114. C. Goujard and L. Cerulus, "Inside Gaia-X: How Chaos and Infighting are Killing Europe's Grand Cloud Project," *Politico*, Oct. 26, 2021, available at <<https://www.politico.eu/article/chaos-and-infighting-are-killing-europes-grand-cloud-project/>> (last accessed January 23, 2023).
115. M. Shabani et al., "Controlled Access under Review: Improving the Governance of Genomic Data Access," *PLOS Biology* 13, no. 12 (2015): e1002339, <https://doi.org/10.1371/journal.pbio.1002339>.
116. M. G. White, "Why Human Subjects Research Protection Is Important," *Ochsner Journal* 20, no. 1 (2020): 16–33, <https://doi.org/10.31486/toj.20.5012>.
117. R.R. Faden et al., *Final Report of the Advisory Committee on Human Radiation Experiments*, DOE/EH – 96001171, available at <<https://bioethicsarchive.georgetown.edu/achre/final/report.html>> (last accessed Jan. 23 2023); see also J. Moreno, *Human Experiments and National Security: The Need to Clarify Policy Center for Bioethics*, University of Penn-

- sylvania Center for Bioethics (2003) available at <[https://repository.upenn.edu/bioethics\\_papers/56](https://repository.upenn.edu/bioethics_papers/56)> (last accessed Jan. 23 2023).
118. Y. Sharma, *New Genetic Research Rules: What Impact on Collaboration?* University World News (7 April 2022) available at <<https://www.universityworldnews.com/post.php?story=20220407145532404>> (last accessed January 23, 2023).
119. K. Needham and C. Tai, *China's Gene Giant Harvests Data from Millions of Women*, Reuters, July 7, 2021, available at <<https://www.reuters.com/investigates/special-report/health-china-bgi-dna/>> (last accessed January 23, 2023).
120. *Id.*
121. *Id.*
122. R. Van Noorden and D. Castelvecchi, News, "Science Publishers Review Ethics of Research on Chinese Minority Groups," *Nature* 576 (2019): 192–193, <https://doi.org/10.1038/d41586-019-03775-y>.
123. K. Hillebrand and L. Hornuf, "The Social Dilemma of Big Data: Donating Personal Data to Promote Social Welfare," *SSRN Electronic Journal* (2021), <https://doi.org/10.2139/ssrn.3801476>; N. Shah et al., "Motivations for Data Sharing—Views of Research Participants from Four European Countries: A DIRECT Study," *European Journal of Human Genetics* 27 (2019): 721–729, <https://doi.org/10.1038/s41431-019-0344-2>.
124. J. Kaiser, "DNA Researchers Question Senate Bill's Security Provisions," *Science* 372 (2021): 1253, <https://doi.org/DOI:10.1126/science.372.6548.1253>.
125. See *supra*, Introduction.
126. United Nations Convention on Biological Diversity, Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from Their Utilization to the Convention on Biological Diversity (2001), available at <<https://perma.cc/3RUP-JSAX>> (last visited January 23, 2023).
127. J. Ambler et al., "Including Digital Sequence Data in the Nagoya Protocol Can Promote Data Sharing," *Trends in Biotechnology* 39 (2021): 116–125, <https://doi.org/10.1016/j.tibtech.2020.06.009>.
128. *Id.*
129. See e.g., S. Das and V. Ni, "Fears over China's Access to Genetic Data of UK Citizens," *The Guardian*, August 20, 2022, available at <<https://www.theguardian.com/science/2022/aug/20/fears-over-chinas-access-to-genetic-data-of-uk-citizens>> (last accessed January 23, 2023).